Global Advanced Drug Delivery CDMO Market Set to Achieve Double-Digit Growth by 2027 Amid Rising Demand for Targeted Therapies

The Global Advanced Drug Delivery CDMO Market is expected to witness a healthy and a double-digit growth rate by 2027. Major advantages offered by advanced drug delivery systems such as targeted and controlled release of new molecules to sites, ease of use, no requirement for frequent dosing, growing demand for safer, more effective methods of administering drugs to patients, evolving landscape of drug molecules, favorable investment by private equity companies and investors are some of the key factors driving the demand for advanced drug delivery systems (ADDSs) and advanced drug delivery CDMOs.

Advanced drug delivery systems are increasingly being used for targeted and controlled release of novel molecules in tissues and cells to optimize their potential benefits for patients.

Explore market trends, size, share and growth report - request a sample copy: https://meditechinsights.com/advanced-drug-delivery-cdmo-market/request-sample/

Major Advantages Offered by Advanced Drug Delivery Systems Fuels the Advanced Drug Delivery CDMO Market Growth

Advanced drug delivery systems have emerged as an easy and accurate method of delivering the drug to a specific site. These systems offer many advantages over traditional systems such as targeted and controlled release of new molecules to sites, consistent absorption of the drug, no requirement of frequent dosing, reduced variability in systemic drug concentrations, and reduction in toxic metabolites. Advanced drug delivery systems optimize drug performance and help deliver superior outcomes, which in turn lead has led to increased demand for advanced drug delivery CDMOs.

"Advanced drug delivery CDMOs will play a pivotal role in advancing the science of drug delivery. The advanced drug delivery technologies will make medicines that are easier to use, and require less frequent dosing, which in turn will enable patients to spend less time managing their diseases."-Senior Scientist, Advanced Drug Delivery CDMO, U.S.A

Private Equity Companies & Investors Investment in Advanced Drug Delivery CDMOs Drives the Global Advanced Drug Delivery CDMO Market

Citing the lucrative growth prospects of the global advanced drug delivery systems market, many private equity companies & investors have invested in the advanced drug delivery CDMO market.

For instance,

In December 2022, EQT Future and ATHOS, alongside other co-investors, invested in SHL Medical, a leading provider of advanced drug delivery solutions

In September 2021, ADQ, an Abu Dhabi-based holding company acquired Acino, a leader in advanced drug delivery systems. Through the investment, ADQ intends to develop an integrated pharma platform including advanced drug development, in-licensing, manufacturing, and commercialization capabilities in select growth-leading markets

Competitive Landscape Analysis: Advanced Drug Delivery CDMO Market

Some of the key players operating in the advanced drug delivery CDMO market are Evonik Health Care, SHL Medical, Lubrizol Life Science, Acino International AG, Pharmathen, Phillips-Medisize (A Molex Company), etc.

Explore the latest trends and deep insights in just one click: https://meditechinsights.com/advanced-drug-delivery-cdmo-market/

Organic and Inorganic Growth Strategies Adopted by the Market Players to Establish Their Foothold in the Advanced Drug Delivery CDMO Market

Players operating in the global advanced drug delivery CDMO market are adopting aggressive growth strategies such as acquiring related firms, launching new products and entering into mergers & collaborations to garner a higher market share.

For instance,

In July 2023, SHL Medical, a leading provider of advanced drug delivery solutions acquired LCA Automation, a Swiss innovative automation solutions provider. The acquisition of LCA Automation is aligned with SHL Medical's strategy to cater to the growing market demand for drug delivery solutions, expand its global presence, and strengthen its vertical capabilities globally

In July 2021, Partners Group, a leading global private markets firm agreed to acquire Pharmathen from from BC Partners. Pharmathen is a leading CDMO specializing in advanced drug delivery technologies for complex generic pharmaceutical products.

The global advanced drug delivery CDMO market is expected to gain a consistent momentum in the forthcoming years due to favorable investments by private equity companies and investors, an increased adoption of controlled-release drug delivery systems by patient populations, and aggressive organic and inorganic growth strategies followed by the global market players.

Top Related Reports:

Vaccine CDMO Market: https://meditechinsights.com/vaccine-cdmo-market/

Biologics CDMO Market: https://meditechinsights.com/global-biologics-cdmo-market/

Lipid Nanoparticles CDMO Market: https://meditechinsights.com/lipid-nanoparticles-cdmo-market/

Orphan Drugs CDMO Market: https://meditechinsights.com/orphan-drugs-cdmo-market/

Contact:

Ruta Halde
Associate, Medi-Tech Insights
Phone: +32 498 86 80 79
Email: info@meditechinsights.com
Website: https://meditechinsights.com/

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

This release was published on openPR.